Published in Aliment Pharmacol Ther on October 09, 2011
Vertical Transmission of Hepatitis C in Adult Children of Female Baby Boomers | NCT03038763
Evaluation of the aspartate aminotransferase/platelet ratio index and enhanced liver fibrosis tests to detect significant fibrosis due to chronic hepatitis C. J Clin Gastroenterol (2014) 1.44
An Increased Ratio of Glycated Albumin to HbA1c Is Associated with the Degree of Liver Fibrosis in Hepatitis B Virus-Positive Patients. Gastroenterol Res Pract (2014) 1.42
Non-invasive assessment of liver fibrosis. Ann Gastroenterol (2012) 1.07
The effectiveness of noninvasive biomarkers to predict hepatitis B-related significant fibrosis and cirrhosis: a systematic review and meta-analysis of diagnostic test accuracy. PLoS One (2014) 1.01
The etiology, diagnosis and prevention of liver cirrhosis: part 1 of a series on liver cirrhosis. Dtsch Arztebl Int (2013) 0.95
Shear-wave elastography for the estimation of liver fibrosis in chronic liver disease: determining accuracy and ideal site for measurement. Radiology (2014) 0.93
The diagnostic value of the FIB-4 index for staging hepatitis B-related fibrosis: a meta-analysis. PLoS One (2014) 0.90
Non-invasive assessment of liver fibrosis in chronic hepatitis B. World J Gastroenterol (2014) 0.85
Impact of contacting study authors to obtain additional data for systematic reviews: diagnostic accuracy studies for hepatic fibrosis. Syst Rev (2014) 0.85
Serum apoptosis markers related to liver damage in chronic hepatitis C: sFas as a marker of advanced fibrosis in children and adults while M30 of severe steatosis only in children. PLoS One (2013) 0.82
Serum zinc value in patients with hepatitis virus-related chronic liver disease: association with the histological degree of liver fibrosis and with the severity of varices in compensated cirrhosis. J Clin Biochem Nutr (2014) 0.80
Non-invasive methods for the diagnosis of nonalcoholic fatty liver disease. World J Hepatol (2015) 0.80
Transient elastography for the detection of hepatic fibrosis in HIV-monoinfected adults with elevated aminotransferases on antiretroviral therapy. AIDS (2015) 0.80
Biomarkers in nonalcoholic fatty liver disease-the emperor has no clothes? World J Gastroenterol (2015) 0.78
Progression of Liver Fibrosis in HIV/HCV Co-Infection: A Comparison between Non-Invasive Assessment Methods and Liver Biopsy. PLoS One (2015) 0.78
Incidence and predictors of hepatic steatosis and fibrosis by serum biomarkers in a large cohort of human immunodeficiency virus mono-infected patients. Open Forum Infect Dis (2015) 0.77
Diagnostic performance of FibroTest, SteatoTest and ActiTest in patients with NAFLD using the SAF score as histological reference. Aliment Pharmacol Ther (2016) 0.77
Diagnostic value of FIB-4 for liver fibrosis in patients with hepatitis B: a meta-analysis of diagnostic test. Oncotarget (2017) 0.77
The Diagnostic Accuracy and Clinical Utility of Three Noninvasive Models for Predicting Liver Fibrosis in Patients with HBV Infection. PLoS One (2016) 0.76
Liver: Usefulness of noninvasive biomarkers of fibrosis in chronic liver disease. Nat Rev Gastroenterol Hepatol (2011) 0.75
Circulating mitochondrial DNA content associated with the risk of liver cirrhosis: a nested case-control study. Dig Dis Sci (2015) 0.75
Evaluation of liver fibrosis: "Something old, something new…". Ann Gastroenterol (2016) 0.75
Elevated liver fibrosis index FIB-4 is not reliable for HCC risk stratification in predominantly non-Asian CHB patients. Medicine (Baltimore) (2016) 0.75
Elastography in Chronic Liver Disease: Modalities, Techniques, Limitations, and Future Directions. Radiographics (2016) 0.75
Validation of Shear Wave Elastography Cutoff Values on the Supersonic Aixplorer for Practical Clinical Use in Liver Fibrosis Staging. Ultrasound Med Biol (2017) 0.75
Drug-resistance genotyping in HIV-1 therapy: the VIRADAPT randomised controlled trial. Lancet (1999) 4.68
Characterization of low- and very-low-density hepatitis C virus RNA-containing particles. J Virol (2002) 4.55
Persistent hepatitis B virus infection in subjects without hepatitis B surface antigen: clinically significant or purely "occult"? Hepatology (2001) 4.28
A proposed system for the nomenclature of hepatitis C viral genotypes. Hepatology (1994) 4.01
Hepatitis C virus type 1b (II) infection in France and Italy. Collaborative Study Group. Ann Intern Med (1995) 3.41
HCV-associated liver cancer without cirrhosis. Lancet (1995) 3.23
Atherogenic dyslipidemia in HIV-infected individuals treated with protease inhibitors. The Swiss HIV Cohort Study. Circulation (1999) 3.16
Specificity of T lymphocyte cytotoxicity to autologous hepatocytes in chronic hepatitis B virus infection: evidence that T cells are directed against HBV core antigen expressed on hepatocytes. J Immunol (1982) 3.09
Peg-IFNα/ribavirin/protease inhibitor combination in hepatitis C virus associated mixed cryoglobulinemia vasculitis: results at week 24. Ann Rheum Dis (2013) 2.99
Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B. Gastroenterology (2004) 2.97
Development of resistance in candida isolates from patients receiving prolonged antifungal therapy. Antimicrob Agents Chemother (1991) 2.81
Antibodies to the surface of halothane-altered rabbit hepatocytes in patients with severe halothane-associated hepatitis. N Engl J Med (1980) 2.41
Visceral adiposity index is associated with significant fibrosis in patients with non-alcoholic fatty liver disease. Aliment Pharmacol Ther (2011) 2.34
Comparison of transient elastography and acoustic radiation force impulse for non-invasive staging of liver fibrosis in patients with chronic hepatitis C. Am J Gastroenterol (2011) 2.31
Clinical and virological profiles in patients with multiple hepatitis virus infections. Gastroenterology (1993) 2.29
Natural history of compensated viral cirrhosis: a prospective study on the incidence and hierarchy of major complications. Gut (2004) 2.22
Detection of low HCV viraemia by repeated HCV RNA testing predicts treatment failure to triple therapy with telaprevir. Aliment Pharmacol Ther (2013) 2.21
Acute hepatitis C infection in HIV positive men who have sex with men in Paris, France, 2001-2004. Euro Surveill (2005) 2.20
Eradication of hepatitis C virus RNA after alpha-interferon therapy. Ann Intern Med (1994) 2.11
Seroconversion from hepatitis B e antigen to anti-HBe in chronic hepatitis B virus infection. Gastroenterology (1980) 2.04
Fibrinogen plasma levels as a marker of thrombin activation: new insights on the role of fibrinogen as a cardiovascular risk factor. Thromb Haemost (1994) 2.03
Recognition of hepatitis B virus envelope proteins by liver-infiltrating T lymphocytes in chronic HBV infection. J Immunol (1989) 2.00
Pharmacologic treatment can prevent pancreatic injury after ERCP: a meta-analysis. Gastrointest Endosc (2000) 1.97
Hyperuricemia is associated with histological liver damage in patients with non-alcoholic fatty liver disease. Aliment Pharmacol Ther (2011) 1.95
Safety and efficacy of interferon-ribavirin combination therapy in HCV-HIV coinfected subjects: an early report. Gut (2000) 1.94
Impact of various handling and storage conditions on quantitative detection of hepatitis C virus RNA. J Hepatol (1996) 1.83
Concurrent hepatitis B and C virus infection and risk of hepatocellular carcinoma in cirrhosis. A prospective study. Cancer (1994) 1.81
Natural history and prognostic factors for chronic hepatitis type B. Gut (1991) 1.75
Selective killing of hepatitis B envelope antigen-specific B cells by class I-restricted, exogenous antigen-specific T lymphocytes. Nature (1990) 1.74
Predicting survival in patients with hepatocellular carcinoma treated by transarterial chemoembolisation. Aliment Pharmacol Ther (2011) 1.73
High prevalence of hepatitis E virus antibody in haemodialysis patients. Lancet (1994) 1.73
Prophylaxis and treatment of hepatitis B in immunocompromised patients. Dig Liver Dis (2007) 1.73
Hepatitis C virus infection in chronic hepatitis B virus carriers. J Infect Dis (1991) 1.69
Validity and reliability of the Italian version of the Chronic Liver Disease Questionnaire (CLDQ-I) for the assessment of health-related quality of life. Dig Liver Dis (2005) 1.69
HIV-1-specific B cell activation. A major constituent of spontaneous B cell activation during HIV-1 infection. J Immunol (1989) 1.66
Changing of hepatitis C virus genotype patterns in France at the beginning of the third millenium: The GEMHEP GenoCII Study. J Viral Hepat (2005) 1.64
Long-term follow-up of acute and chronic non-A, non-B post-transfusion hepatitis: evidence of progression to liver cirrhosis. Gut (1982) 1.60
Identification of an attachment site for human liver plasma membranes on hepatitis B virus particles. Virology (1989) 1.59
Reliability of liver stiffness measurement in non-alcoholic fatty liver disease: the effects of body mass index. Aliment Pharmacol Ther (2011) 1.58
Hepatitis C virus genotyping based on 5' noncoding sequence analysis (Trugene). J Clin Microbiol (2001) 1.56
Incorrect echocardiographic diagnosis in patients with mechanical prosthetic valve dysfunction: correlation with surgical findings. Am J Med (2000) 1.55
Epidemiological and virological analysis of couples infected with hepatitis C virus. Gut (1999) 1.55
Performance of noninvasive markers for liver fibrosis is reduced in chronic hepatitis C with normal transaminases. J Viral Hepat (2007) 1.54
Comparison of three algorithms of non-invasive markers of fibrosis in chronic hepatitis C. Aliment Pharmacol Ther (2011) 1.51
Modified spleen stiffness measurement by transient elastography is associated with presence of large oesophageal varices in patients with compensated hepatitis C virus cirrhosis. J Viral Hepat (2013) 1.51
Long-term follow-up of non-A, non-B (type C) post-transfusion hepatitis. J Hepatol (1992) 1.50
Mediterranean Adequacy Index: correlation with 25-year mortality from coronary heart disease in the Seven Countries Study. Nutr Metab Cardiovasc Dis (2004) 1.49
Natural occurrence of scrapie in goats in Italy. Vet Rec (1998) 1.49
Nitric oxide pathway, Ca2+, and serotonin content in platelets from patients suffering from chronic daily headache. Cephalalgia (1999) 1.48
Is oxidative stress the missing link between insulin resistance and atherosclerosis? Diabetologia (1995) 1.45
Effect of pregnancy on chronic hepatitis C: a case-control study. Lancet (2000) 1.43
Interferon antibodies in patients with chronic hepatitic C virus infection treated with recombinant interferon alpha-2 alpha. J Hepatol (1994) 1.43
Dispersal flight by Triatoma infestans in an arid area of Argentina. Med Vet Entomol (1988) 1.43
T-lymphocyte cytotoxicity to HBsAg-coated target cells in hepatitis b virus infection. Gut (1977) 1.42
Food habits in a southern Italian town (Nicotera) in 1960 and 1996: still a reference Italian Mediterranean diet? Diabetes Nutr Metab (2001) 1.41
ICHD 2nd Edition: Some considerations on the application of criteria for primary headache. Cephalalgia (2005) 1.41
HCV genotype 1 subtypes (1a and 1b): similarities and differences in clinical features and therapeutic outcome. Hepatol Int (2014) 1.41
Impact of TT virus infection in acute and chronic, viral- and non viral-related liver diseases. J Hepatol (2000) 1.40
Evaluation and improvement of a reliable diagnosis of cirrhosis by blood tests. Gastroenterol Clin Biol (2008) 1.39
Triggering of acute alcoholic hepatitis by alpha-interferon therapy. J Hepatol (1999) 1.39
Liver-related mortality in human-immunodeficiency-virus-infected patients between 1995 and 2003 in the French GERMIVIC Joint Study Group Network (MORTAVIC 2003 Study). J Viral Hepat (2007) 1.39
Mees' lines due to cyclosporin. Br J Dermatol (1999) 1.39
Reciprocal interactions between human immunodeficiency virus and hepatitis C virus infections. Clin Infect Dis (1996) 1.39
Variability of the area under the receiver operating characteristic curves in the diagnostic evaluation of liver fibrosis markers: impact of biopsy length and fragmentation. Aliment Pharmacol Ther (2007) 1.38
Clinical, virologic and histologic outcome following seroconversion from HBeAg to anti-HBe in chronic hepatitis type B. Hepatology (1986) 1.38
[Coronary angioplasty in an Italian hospital without on-site cardiac surgery: the results and outlook]. G Ital Cardiol (1994) 1.38
The new paradigm of hepatitis C therapy: integration of oral therapies into best practices. J Viral Hepat (2013) 1.37
Transarterial oily chemoembolization for the treatment of hepatocellular carcinoma: a multivariate analysis of prognostic factors. Hepatology (1994) 1.37
Intracellular Mg++ concentration and electromyographical ischemic test in juvenile headache. Cephalalgia (1999) 1.37
Meta-analysis: the outcome of anti-viral therapy in HCV genotype 2 and genotype 3 infected patients with chronic hepatitis. Aliment Pharmacol Ther (2008) 1.36
Risk factors for hepatitis C virus transmission to health care workers after occupational exposure: a European case-control study. Clin Infect Dis (2005) 1.35
Liver cell surface localization of hepatitis B antigen and of immunoglobulins in acute and chronic hepatitis and in liver cirrhosis. Clin Exp Immunol (1976) 1.35
Risk factors and outcome among a large patient cohort with community-acquired acute hepatitis C in Italy. Clin Infect Dis (2006) 1.34
Nitric oxide metabolites, prostaglandins and trigeminal vasoactive peptides in internal jugular vein blood during spontaneous migraine attacks. Cephalalgia (2000) 1.32
Detection of a new antibody system reacting with Dane particles in hepatitis B virus infection. Br Med J (1978) 1.31
Epidemiological characteristics and response to peginterferon plus ribavirin treatment of hepatitis C virus genotype 4 infection. J Viral Hepat (2007) 1.29
Treatment of hepatitis C virus-related cirrhosis: a randomized, controlled trial of interferon alfa-2b versus no treatment. Hepatology (1999) 1.29
Liver resection and needle liver biopsy cause hematogenous dissemination of liver cells. Hepatology (1999) 1.28
Fibrosis progression in initially mild chronic hepatitis C. J Viral Hepat (2006) 1.26
Differential distribution of hepatitis B core and E antigens in hepatocytes: analysis by monoclonal antibodies. Hepatology (1986) 1.26
Epidemiological changes in hepatitis C virus genotypes in France: evidence in intravenous drug users. J Viral Hepat (2002) 1.25
Lack of correlation between hepatitis C virus genotypes and clinical course of hepatitis C virus-related cirrhosis. Hepatology (1997) 1.24
Persisting long-term benefit of genotype-guided treatment for HIV-infected patients failing HAART. The Viradapt Study: week 48 follow-up. Antivir Ther (2000) 1.24
Core antigen-specific immunoglobulin G bound to the liver cell membrane in chronic hepatitis B. Gastroenterology (1982) 1.24
Influence of hepatitis delta virus infection on progression to cirrhosis in chronic hepatitis type B. J Infect Dis (1987) 1.23
Long-term follow-up of anti-HBe-positive chronic active hepatitis B. Hepatology (1988) 1.23
Biomarkers predictive for clinical efficacy of taxol-based chemotherapy in advanced breast cancer. Ann Oncol (2005) 1.22
Liver cell apoptosis in chronic hepatitis C correlates with histological but not biochemical activity or serum HCV-RNA levels. Hepatology (2000) 1.21
Long-term follow-up of the hepatitis C HENCORE cohort: response to therapy and occurrence of liver-related complications. J Viral Hepat (2007) 1.21